The specter of generic rivalry has long loomed around copyright’s famous drug, Sildenafil, triggering questions about the prospects of connected drug holdings. While initial years saw significant gains, the exclusivity expiration has opened the path for discounted substitutes, possibly diminishing profitability and posing a significant risk for s